SCHEMBL5361806

SCHEMBL5361806

O=C1CN(c2cc3c(cc2F)c(=O)c(-c2noc(Cc4ccc(F)cc4)n2)cn3Cc2ccc(C(F)(F)F)cc2F)CCN1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.35
RIPK3 Q9Y572 3/20 0.33
S1PR1 P21453 1/20 0.33
S1PR3 Q99500 1/20 0.33
TOP1 P11387 2/20 0.33
KDM4E B2RXH2 3/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
HSD17B10 Q99714 2/20 0.32
BRD4 O60885 1/20 0.32
TSHR P16473 1/20 0.32
HTT P42858 1/20 0.32
CYP2J2 P51589 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GRM2 Q14416 1/20 0.32
THRB P10828 3/20 0.31
MEN1 O00255 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5360483 0.88 LMNA (0.40) LMNAKDM4EALDH1A1HPGDMEN1
SCHEMBL5361098 0.87 LMNA (0.41) LMNATOP1KDM4EALDH1A1HPGD
SCHEMBL5361869 0.85 LMNA (0.39) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL5358434 0.83 LMNA (0.41) LMNATOP1KDM4EALDH1A1HPGD
SCHEMBL5354409 0.83 ALDH1A1 (0.43) LMNAKDM4EALDH1A1HPGDTHRB
SCHEMBL5355982 0.82 LMNA (0.43) LMNATOP1KDM4EALDH1A1HPGD
SCHEMBL5361332 0.81 THRB (0.43) LMNATOP1KDM4EALDH1A1HPGD
SCHEMBL5364347 0.81 ALDH1A1 (0.43) LMNAKDM4EALDH1A1HPGDMEN1
SCHEMBL14351189 0.80 LMNA (0.39) LMNARIPK3TOP1KDM4EALDH1A1
SCHEMBL5362494 0.80 LMNA (0.41) LMNAKDM4EALDH1A1HPGDTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US claimed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 LMNA 4460/4885RIPK3 3304/4885S1PR1 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.